Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule product candidates primarily to treat cancer. Co. has three clinical-stage product candidates and preclinical programs. Substantially all of Co.'s effort is focused on its primary product candidate, rigosertib, which has been tested in an intravenous formulation as a single agent for patients with higher-risk myelodysplastic syndromes (MDS), and an oral formulation as a single agent in lower risk MDS or in combination with azacitidine for patients with higher-risk MDS. Co.'s other product candidate, Briciclib, is a small molecule targeting an intracellular regulatory protein, Cyclin D1. We show 31 historical shares outstanding datapoints in our ONTX shares outstanding history coverage, used to compute ONTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ONTX market cap history over the course of time is important for investors
interested in comparing ONTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ONTX versus a peer is one thing; comparing
ONTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ONTX can fluctuate over the course of history.
With this page we aim to empower investors researching ONTX by allowing them to research the ONTX market cap history. |
Free ONTX Email Alerts:
Video: The Importance of Market Cap
